Franklin Resources Inc. Boosts Holdings in Context Therapeutics Inc. (NASDAQ:CNTX)

Franklin Resources Inc. grew its position in shares of Context Therapeutics Inc. (NASDAQ:CNTX - Free Report) by 115.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 4,003,380 shares of the company's stock after acquiring an additional 2,149,392 shares during the quarter. Franklin Resources Inc. owned 5.34% of Context Therapeutics worth $4,204,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the company. State Street Corp boosted its stake in shares of Context Therapeutics by 21.5% in the 3rd quarter. State Street Corp now owns 111,907 shares of the company's stock worth $219,000 after buying an additional 19,800 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in Context Therapeutics in the third quarter worth $89,000. Finally, Clear Harbor Asset Management LLC grew its stake in Context Therapeutics by 60.6% in the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock valued at $61,000 after purchasing an additional 21,804 shares during the period. 14.03% of the stock is owned by hedge funds and other institutional investors.

Context Therapeutics Trading Down 3.9 %

Shares of NASDAQ CNTX traded down $0.03 during midday trading on Thursday, hitting $0.83. The company's stock had a trading volume of 8,090 shares, compared to its average volume of 402,771. The stock has a fifty day moving average price of $0.77 and a 200 day moving average price of $1.25. The firm has a market capitalization of $74.54 million, a price-to-earnings ratio of -0.91 and a beta of 2.18. Context Therapeutics Inc. has a one year low of $0.55 and a one year high of $2.75.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. On average, equities research analysts predict that Context Therapeutics Inc. will post -0.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

CNTX has been the topic of a number of recent analyst reports. Citizens Jmp upgraded Context Therapeutics to a "strong-buy" rating in a research note on Wednesday, January 8th. HC Wainwright reaffirmed a "buy" rating and issued a $5.00 price objective on shares of Context Therapeutics in a research report on Friday, March 21st. JMP Securities started coverage on shares of Context Therapeutics in a research report on Wednesday, January 8th. They set an "outperform" rating and a $4.00 target price for the company. Finally, D. Boral Capital reaffirmed a "buy" rating and issued a $9.00 price target on shares of Context Therapeutics in a report on Wednesday, April 9th. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Context Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $6.17.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.